Chugai Pharmaceutical Co., the Japanese unit of Roche Holding AG, said Tuesday its first-half profit fell 10 percent on lower sales of the antiviral drug Tamiflu and after the company ended a partnership with Sanofi-Aventis SA.
Net profit dropped to about ¥18.9 billion from ¥21.1 billion a year earlier, Chugai Pharma said in a statement to the Tokyo Stock Exchange. The result exceeded an April forecast of ¥15.5 billion, while sales retreated to ¥145.9 billion, missing a forecast by 2.8 percent.
Tamiflu sales fell 93 percent to ¥1.6 billion after the government completed its plans for stockpiling the drug against a pandemic.